States / Tennessee / SB 421

SB 421 In Committee

Opioids - As enacted, clarifies that a physician licensed in this state is the only healthcare provider authorized to prescribe a buprenorphine product for a FDA-approved use in recovery or medication-assisted treatment; revises criteria for providers not licensed in this state to prescribe a buprenorphine product for the treatment of opioid use disorder. - Amends TCA Title 33; Title 41; Title 53 and Title 63.

Introduced
In Committee
Floor
Crossed Over
Passed
Enacted
Apr 28, 2025 · House
Comp. became Pub. Ch. 295
Apr 7, 2025 · House
Sponsor(s) Added.
Apr 7, 2025 · House
Companion House Bill substituted
Apr 4, 2025 · House
Placed on Senate Regular Calendar for 4/7/2025
Apr 3, 2025 · House
Senate Reset on calendar for 4/7/2025
Apr 1, 2025 · House
Placed on Senate Regular Calendar for 4/3/2025
Mar 31, 2025 · House
Sponsor(s) Added.
Mar 31, 2025 · House
Senate Reset on calendar for 4/3/2025
Mar 28, 2025 · House
Placed on Senate Regular Calendar for 3/31/2025
Mar 24, 2025 · House
Sponsor(s) Added.
Mar 24, 2025 · House
Senate Reset on calendar for 3/31/2025
Mar 21, 2025 · House
Placed on Senate Regular Calendar for 3/24/2025
Mar 17, 2025 · House
Senate Reset on calendar for 3/27/2025
Mar 14, 2025 · House
Placed on Senate Regular Calendar for 3/17/2025
Mar 11, 2025 · Senate
Recommended for passage with amendment/s, refer to Senate Calendar Committee Ayes 9, Nays 0 PNV 0
Mar 5, 2025 · House
Placed on Senate Judiciary Committee calendar for 3/11/2025
Feb 25, 2025 · House
Action deferred in Senate Judiciary Committee to 3/11/2025
Feb 19, 2025 · House
Placed on Senate Judiciary Committee calendar for 2/25/2025
Feb 12, 2025 · Senate
Passed on Second Consideration, refer to Senate Judiciary Committee
Feb 10, 2025 · House
Introduced, Passed on First Consideration
Jan 28, 2025 · House
Filed for introduction